KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. (Q54497664)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

0 references

author name string

Suniti Bhaumik

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

Rajatava Basu

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

Subha Sen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

Kshudiram Naskar

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

Syamal Roy

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

language of work or name

0 references

publication date

20 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

27

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

1306-1316

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4 and CD8 T cell responses and protection against leishmania major infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63).

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Recombinant interleukin 12 cures mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

The immunology of susceptibility and resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

IL-12 is required to maintain a Th1 response during Leishmania major infection.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4( ) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4 T cells which are NK1.1-

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8 T-cell responses.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8 cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

CD40 Signaling Is Impaired in L. major–infected Macrophages and Is Rescued by a p38MAPK Activator Establishing a Host-protective Memory T Cell Response

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

The central memory CD4 T cell population generated during Leishmania major infection requires IL-12 to produce IFN-gamma

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

CD8 T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8 T cells

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.12.053

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.12.053

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19162111

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54497664&oldid=1368957937"